Em­maus re­scinds EU mar­ket­ing ap­pli­ca­tion, fol­low­ing neg­a­tive re­view

Two years ago, Em­maus Life Sci­ences se­cured FDA ap­proval for its sick­le cell dis­ease (SCD) ther­a­py — mark­ing the first new ap­proval for pa­tients af­fect­ed by the group of in­her­it­ed red blood cell dis­or­ders that typ­i­cal­ly af­flict those of African an­ces­try in two decades. But the Eu­ro­pean reg­u­la­tor was not sat­is­fied with the dataset sup­port­ing the ther­a­py  — prompt­ing its mak­er on Thurs­day to re­scind its ap­pli­ca­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER